Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells.

Virginia College of Osteopathic Medicine, Blacksburg, VA 24060, USA.
Clinical & Experimental Immunology (Impact Factor: 3.28). 07/2009; 156(3):542-51. DOI: 10.1111/j.1365-2249.2009.03924.x
Source: PubMed

ABSTRACT Recent reports show that 5-amino-4-imidazole carboxamide riboside (AICAR), a pharmacological activator of AMP-activated protein kinase (AMPK), inhibits the lipopolysaccharide (LPS)-induced production of proinflammatory cytokines. MRL/MPJ-Fas(lpr) (MRL/lpr) mice show an intrinsic decreased threshold for the production of inflammatory mediators when stimulated. In our current studies, we sought to determine if AMPK activation would inhibit inflammatory mediator production in stimulated kidney mesangial cells. Cultured mesangial cells from MRL/lpr mice were treated with AICAR and stimulated with LPS/interferon (IFN)-gamma. AICAR decreased dose-dependently inducible nitric oxide synthase (iNOS), cyclooxygenase-2 and interleukin-6 production in LPS/IFN-gamma-stimulated mesangial cells. Mechanistically, AICAR inhibited the LPS/IFN-gamma-stimulated PI3K/Akt signalling inflammatory cascade but did not affect LPS/IFN-gamma-mediated inhibitory kappa B phosphorylation or nuclear factor (NF)-kappaB (p65) nuclear translocation. Treatment with the adenosine kinase inhibitor 5'-iodotubercidin blocked the ability of AICAR to activate AMPK and prevented AICAR from inhibiting the LPS/IFN-gamma-stimulated PI3K/Akt pathway and attenuating iNOS expression. Taken together, these observations suggest that AICAR inhibits LPS/IFN-gamma-induced Akt phosphorylation through AMPK activation and may serve as a potential therapeutic target in inflammatory diseases.

  • [Show abstract] [Hide abstract]
    ABSTRACT: AMP-activated protein kinase (AMPK) activation plays a central role in cellular metabolic homeostasis. Although AMPK is known for its roles in energy homeostasis, numerous recent studies have suggested broader protective roles in inflammation and hypertension. Chemokine CCL5 has shown down-regulatory effects on angiotensin II (Ang II)-induced hypertensive mediators as well as VSMCs proliferation in spontaneously hypertensive rats (SHR) VSMCs. In the present study, we investigated the relationship between CCL5 and AMPK in the anti-hypertensive effects of CCL5 in SHR VSMCs. CCL5 increased AMPK phosphorylation and attenuated Ang II-induced AMPK inhibition. AMPK activation induced by CCL5 was mediated mainly through the AT2 R pathway. Activation of dimethylarginine dimethylaminohydrolase (DDAH)-1 by CCL5 resulted in AMPK activation as well as attenuation of Ang II-induced AMPK inhibition. In addition, AMPK activation induced by CCL5 was partially responsible for the inhibitory effects of CCL5 on Ang II-induced 12-lipoxygenase (12-LO) and endothelin (ET)-1 expression, and the inhibitory effect of CCL5 on Ang II-induced VSMCs proliferation was also mediated via AMPK activation in SHR VSMCs. In conclusion, CCL5 induces activation of AMPK via DDAH-1 activity in SHR VSMCs, and activation of AMPK is partially responsible for the inhibitory effects of CCL5 on Ang II-induced hypertensive mediators. These results suggest that activation of AMPK by CCL5 potentially expands the anti-hypertensive role of CCL5 in SHR VSMCs.
    Cytokine 01/2014; · 2.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT The aims of the present study were to examine the effect of AMPK activation on pulmonary arterial smooth muscle cells (PASMCs) proliferation and to address its potential mechanisms. ET-1 dose and time-dependently induced PASMCs proliferation, and this effect was suppressed by a selective AMPK activator metformin. The results of the study further indicated that the proliferation of PASMCs stimulated by ET-1 was associated with the increase of Skp2 and decrease of p27, and metformin reversed ET-1-induced Skp2 elevation and raised p27 protein level. Our study suggests that activation of AMPK suppresses PASMCs proliferation and has potential value in negatively modulating pulmonary vascular remodeling and therefore could prevent or treat the development of pulmonary arterial hypertension (PAH).
    Experimental Lung Research 06/2014; 40(5):251-8. · 1.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genistein, an isoflavone derivative found in soy, is known as a promising treatment for rheumatoid arthritis (RA). However, the detailed molecular mechanism of genistein in suppression of proinflammatory cytokine production remains ambiguous. The aim of this work was to evaluate the signal pathway by which genistein modulates inflammatory cytokine expression. MH7A cells were stimulated with tumor necrosis factor (TNF)-α and incubated with genistein, and interleukin (IL)-1β, IL-6, and IL-8 production was measured by enzyme-linked immunosorbent assay. Nuclear translocation of nuclear factor (NF)-κB was measured by a confocal fluorescence microscopy. The intracellular accumulation of reactive oxygen species (ROS) was monitored using the fluorescent probe 5-6-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate. Signal-transduction protein expression was measured by Western blot. Genistein decreased the secretion of IL-1β, IL-6, and IL-8 from TNF-α-stimulated MH7A cells in a dose-dependent manner. Genistein prevented TNF-α-induced NF-κB translocation as well as phosphorylation of IκB kinase-α/β and IκBα, and also suppressed TNF-α-induced AMPK inhibition. The production of IL-1β, IL-6, and IL-8 induced by TNF-α was decreased by the phosphatidylinositol-3 kinase inhibitor LY294002, suggesting that inhibition of Akt activation might inhibit IL-1β, IL-6, and IL-8 production induced by TNF-α. In addition, we also found that pretreatment with the adenosine monophosphate-activated protein kinase (AMPK) agonist 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside obviously inhibited TNF-α-induced proinflammatory cytokine production. These observations suggest that the inhibitory effect of genistein on TNF-α-induced proinflammatory cytokine production is dependent on AMPK activation. These findings indicate that genistein suppressed TNF-α-induced inflammation by inhibiting the ROS/Akt/NF-κB pathway and promoting AMPK activation in MH7A cells.
    Drug Design, Development and Therapy 01/2014; 8:315-23. · 3.03 Impact Factor

Full-text (2 Sources)

Available from
Jun 6, 2014